Locations:
Search IconSearch
September 23, 2020/Digestive/GI

Entrustable Professional Activities Established for Advanced IBD Fellowships

On the purpose, process and results

Medical education

A task force formed by the American College of Gastroenterology (ACG) and The Crohn’s & Colitis Foundation and led by Cleveland Clinic’s Benjamin Cohen, MD, MAS, has established entrustable professional activities (EPAs) for advanced inflammatory bowel disease (IBD) fellowship training in the United States. The 10 EPAs were published simultaneously in The American Journal of Gastroenterology and Inflammatory Bowel Diseases.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“We’ve had advanced IBD fellowships for years now that try to bridge the gaps in knowledge gained in a gastroenterology fellowship and knowledge required to be an IBD specialist,” notes Dr. Cohen, Clinical Director for Inflammatory Bowel Disease in the Department of Gastroenterology, Hepatology & Nutrition of Cleveland Clinic’s Digestive Diseases & Surgery Institute. “But there has been no common curriculum, no established outcomes and no consensus as to what constitutes an IBD specialist. The task force set out to change that.”

Methods of development

The task force developed the EPAs using a multistep approach with a three-phase modified Delphi method. Focus groups developed an initial set of EPAs, which were critiqued using an iterative model of feedback from program directors and other experts. The resulting EPAs then underwent two rounds of digital voting, which narrowed the pool to 15 potential EPAs. The task force then narrowed the selection to 10 EPAs via two rounds of web-based voting and a live consensus meeting. Once the final 10 were established, the task force mapped EPAs to curricular milestones.

“The process was interesting and methodical because at every step of the way we were including feedback from a diverse, carefully selected task force. The task force included IBD experts at different points in their career paths, from many geographic practice locations and practice types, fellowship directors and medical educators,” says Dr. Cohen. “It took time to do it in this manner, but we wanted to make sure we got it right.”

Advertisement

The EPAs

EPAs are part of the competency-based medical education approach that has occurred in graduate medical education in the last decade. EPAs distinguish a particular subspecialty by defining what tasks a practitioner should be capable of performing unsupervised in a clinical setting. “We gave special consideration to what an EPA for a general gastroenterologist should be — which all IBD specialists should already have since they’ve completed a fellowship — as distinguished from what EPAs are required to be an IBD specialist,” notes Dr. Cohen. “Defining these skills will be important not only for trainees, but also for patients who expect a high level of expertise.”

The 10 EPAs are:

  1. Classify IBD phenotype, disease activity and extraintestinal manifestations.
  2. Utilize advanced diagnostic and therapeutic endoscopic and radiographic techniques in the management of IBD.
  3. Prescribe and manage evidence-based IBD therapies utilizing clinical pharmacological principles in clinical practice.
  4. Manage adverse events and complications of IBD and IBD therapies.
  5. Manage hospitalized patients with IBD.
  6. Manage pre- and postoperative care for IBD patients.
  7. Manage IBD in special populations.
  8. Recognize the importance of psychobehavioral health in IBD and implement psychosocial support strategies.
  9. Evaluate and manage nutritional health status in IBD patients
  10. Apply preventive health strategies for IBD patients in accordance with guidelines.

For detailed descriptions of each, as well as the knowledge, skills and attitudes (KSAs) that determine competency, read the full article in Inflammatory Bowel Disease.

Advertisement

Related Articles

Qazi, MD
June 4, 2021/Digestive/GI
Biosimilar Safety and Efficacy Comparable to Biologic Treatment in IBD Patients

Infliximab-abda offers similar benefits at lower costs

20-DDI-1983916-ACG-Decreasing-Colectomy-UC-Biologic-Medications
October 26, 2020/Digestive/GI
20 Years of Colectomy and Biologics for Ulcerative Colitis

How rates of colectomy and biologics use have changed over time

Dr. Lavryk with scope
May 29, 2025/Digestive/Case Study
Reviving the K-Pouch: Cleveland Clinic's Unique Solution for a Patient with FAP

Radiation to the pelvis from cancer treatment made the traditional treatment path unavailable

Physician speaking with patient
May 20, 2025/Digestive/Research
Luminal GI Cancers Driving the Rise in Early-Onset GI Cancer Rates

Greater awareness among young patients is needed

Physician with RFA device
May 19, 2025/Digestive/Research
New Approach Reduces Mortality, Complications in Malignant Biliary Obstruction

Combining RFA with stenting improves survival rates, reduces post-ERCP complications

Dr. Liska speaking with researcher
May 14, 2025/Digestive/Research
Rectal Cancer Patients with IBD Do Not Respond as Well to Neoadjuvant Therapy

Poor response may be due to different tumor biology

Dr. Gorgun in surgery
May 13, 2025/Digestive/Research
Rectal Cancer: Local Regrowth After TNT Does Not Increase Risk of Distant Metastasis

Study sheds light on distant metastasis rates between upfront surgery and Watch & Wait strategies

Ad